Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling [0.03%]
巨噬细胞凋亡细胞摄取介导的脂肪酸再利用使肿瘤细胞代谢性抵抗免疫检查点治疗
Zhixian Liang,Xiaohang Long,Zhewen Xiong et al.
Zhixian Liang et al.
Tumor cells metabolically adapt to the nutrient-deprived tumor microenvironment (TME). However, the metabolic plasticity underlying immune-checkpoint blockade (ICB) adaptation remains unclear. Here, we report that tumor cells exploit macrop...
Barbara Pistilli,Raffaele Colombo,Maria Fernanda Mosele et al.
Barbara Pistilli et al.
Antibody-drug conjugates (ADCs) represent a growing therapeutic class in oncology marked by several transformative clinical successes. However, these exceptional outcomes remain restricted to a limited number of tumor types, and ADC develop...
Vincent Liu,Katalin Sandor,Patrick K Yan et al.
Vincent Liu et al.
Innate immune cells constitute the majority of the tumor microenvironment (TME) and mediate anti-tumor immunity and immunotherapy responses. While single-cell T and B cell receptor sequencing have revealed insights into the clonal dynamics ...
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma [0.03%]
低氧诱导的代谢改变可同时促进肾细胞癌对免疫治疗的反应和抗药性
Lynda Vuong,Andrew E Cornish,Jennifer Pfeil et al.
Lynda Vuong et al.
Vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors (VEGFR-TKIs) and anti-PD-1 (aPD-1) combinations are effective in multiple solid tumors, particularly in clear cell renal cell carcinoma (ccRCC), due to its cha...
Julius C Enssle,Björn Häupl,Arber Qoku et al.
Julius C Enssle et al.
The clinical and molecular heterogeneity of diffuse large B cell lymphoma (DLBCL) is incompletely understood. By integrating proteomic, transcriptomic, and genomic data from 478 DLBCL tumors, we identify seven DLBCL proteogenotypes (PGs) re...
Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2 [0.03%]
斑马鱼斑马鱼 Hippo 信号通过 Skp2 抑制细胞 DNA 倍体和致瘤性
Shihao Zhang,Qinghua Chen,Qingxu Liu et al.
Shihao Zhang et al.
Published Erratum
Cancer cell. 2026 Jun 4:S1535-6108(26)00266-7. DOI:10.1016/j.ccell.2026.05.021 2026
Charles Dumontet
Charles Dumontet
Resistance to antibody drug conjugates (ADCs) may be due to low target antigen expression resulting in reduced intracellular payload concentration. In this issue of Cancer Cell, Wang et al. show that increased target antigen NECTIN4 express...
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration [0.03%]
靶向肿瘤内在的STK40诱导免疫脆弱性并促进T细胞再激活
Lili Zhu,Sisi Zhang,Botai Li et al.
Lili Zhu et al.
Immunotherapy has revolutionized cancer treatment, yet its efficacy in hepatocellular carcinoma (HCC) remains limited and the mechanisms of resistance are poorly defined. Using in vivo CRISPR-Cas9 screens, we identify serine/threonine kinas...
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer [0.03%]
逃避免疫吞噬作用可使抗体-药物偶联物治疗失效
Yuzhao Wang,Zibin Chen,Weikai Wang et al.
Yuzhao Wang et al.
Enfortumab vedotin (NECTIN4-ADC), a NECTIN4-targeting antibody-drug conjugate, has shown substantial efficacy in urothelial carcinoma, yet primary and acquired resistance remain major barriers to durable benefit. By integrating paired spati...
Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation [0.03%]
重塑HER2治疗：连接癌基因依赖性和免疫调节
Luke Tillman,Lajos Pusztai,Seth A Wander et al.
Luke Tillman et al.
Human epidermal growth factor receptor 2 (HER2, encoded by ERBB2) is an oncogenic driver in multiple cancers. Beyond canonical signaling, HER2 remodels the tumor microenvironment by suppressing antigen presentation, enhancing checkpoint exp...